The global follicle stimulating hormone market size is expected to gain a steady CAGR and expected to bypass USD 1.49 billion in the upcoming years. It is a common occurrence of bone loss in menopausal women and follicle stimulating hormone (FSH) studies are proving beneficial to develop diagnostic procedures with an objective to control bone loss in middle-aged women population. According to the findings by Journal of Bone and Mineral Research, FSH tests can indicate the level of bone loss mainly at lumbar spine in the menopausal phase. Therefore, menopause can be an early indicator to prevent any extreme severity in the event of bone loss. Effects of Follicle Stimulating Hormone on Infertility and Bone Loss: Middle-aged women undergo hormone transformation prior to menopause and oestrogen deficiency. Rise in FSH levels before decline of oestrogen can be a possible cause for occurrence of menopausal stage. In another case, FSH serum levels in young women differ in physiological conditions during menstrual cycles leading in condition of premature ovarian insufficiency (POI) and polycystic ovarian syndrome (PCOS). This develops a stage of infertility for prolonged period, thus demanding a detailed clinical investigation of formation of follicles and consistency in menstrual cycles. Access "109" page research report with TOC on "Follicle Stimulating Hormone Market" available with Radiant Insights, [email protected] https://www.radiantinsights.com/research/global-follicle-stimulating-hormone-market-2020-2026 In older women, pituitary hormones have a huge significance for bone regulation. Hence, the risk of developing osteoporosis in middle-aged and older women is much high as there is decline in oestrogen levels. The commercial developments to counter hormone related issues are ongoing. For example, Ovaleap (XM17) is a recombinant human FSH (r-hFSH) product approved in 2013 by European Medicines Agency (EMA). It is a biosimilar medicinal product in line with Gonal-f and is mainly intended for women to regulated ovarian stimulation. Global Outlook: The global market is majorly driven by regular occurrences of infertility cases in men and women resulting out of unhealthy lifestyle and increase in alcohol consumption. Moreover, rise in use of assisted reproductive technology (ART) is propelling the market growth in the near future. Apart, the beneficial outcomes of FSH tests and diagnostics have triggered its use in determining bone loss in middle-aged women. Genomic based studies are gaining market traction attributing to their significance. Regional outlook: Asia Pacific is an emerging market mainly driven by enormous demands for synthetic products and rise in research initiatives. Presence of large patient pool and growing demand for gynaec consultations is most likely to drive the regional markets of India and China. Moreover, presence of qualified physicians and development of research infrastructure ensures a sustainable market growth. Common occurrences of polycystic ovary syndrome (PCOS) in women of reproductive age across India, China and Japan is influential for the clinical studies. It is also anticipated that there will be a high population of premenopausal women in the next five years that is much favorable for FSH diagnosis and tests. Some of the key players in the follicle stimulating hormone market are MSD, Merck Serono, IBSA, Livzon, Ferring, GenScience Pharmaceuticals Co. Ltd, Gedeon Richter, Teva and Techwell.
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.